Overview
Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease
Status:
Completed
Completed
Trial end date:
2007-12-01
2007-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Prana Biotechnology Limited
Criteria
Inclusion Criteria:- diagnosis of probable early Alzheimer's disease
- stable dose of acetylcholinesterase inhibitor
- community dwelling
- stable medical condition
Exclusion Criteria:
- unstable and significant medical conditions
- recurrent major psychiatric disorder
- treatment with memantine